Core Insights - Bristol Myers Squibb (BMY) has received FDA acceptance for the new drug application (NDA) of iberdomide, in combination with daratumumab and dexamethasone, for treating relapsed or refractory multiple myeloma (RRMM) [1][7] - The FDA has granted a priority review for the NDA, with a decision expected on August 17, 2026 [1] - Iberdomide is part of a new class of drugs known as cereblon E3 ligase modulators (CELMoDs), which are under investigation for RRMM treatment [2][8] BMY's Price Performance - Over the past six months, BMY shares have increased by 24.8%, outperforming the industry average rise of 21.4% [3] Iberdomide Development - The NDA filing is based on data from the phase III EXCALIBER-RRMM study, which showed a statistically significant improvement in minimal residual disease (MRD) negativity rates compared to the control arm [4][7] - The study is ongoing, with patients being assessed for progression-free survival [5] Regulatory Designations - Iberdomide has received Breakthrough Therapy designation from the FDA for the treatment of RRMM [2][7] - The review process is part of the FDA's Project Orbis initiative, allowing simultaneous evaluation by regulatory authorities in other countries [8] Strategic Focus - The successful development of iberdomide and other key pipeline candidates is crucial for Bristol Myers as it aims to expand and diversify its portfolio amid challenges from generic competition [9]

Core Insights - Bristol Myers Squibb (BMY) announced positive data from the late-stage study on iberdomide for patients with relapsed or refractory multiple myeloma (RRMM) [1][8] - The phase III EXCALIBER-RRMM study demonstrated statistically significant improvement in minimal residual disease (MRD) negativity rates compared to the control arm [2][8] - The study is designed to assess dual-primary endpoints of MRD negativity and progression-free survival (PFS), with additional secondary endpoints including overall survival (OS) and health-related quality of life [3] Study Details - The EXCALIBER-RRMM study is a multicenter, two-stage, randomized, open-label trial evaluating iberdomide in combination with Darzalex and dexamethasone versus Darzalex, bortezomib, and dexamethasone [1][3] - The safety profile of iberdomide in combination with daratumumab and dexamethasone is consistent with previous studies, and the trial will continue to evaluate PFS and OS [4] - BMY plans to discuss the results with health authorities as iberdomide represents a novel class of medicines called CELMoDs, which may change the treatment landscape for multiple myeloma [5] Portfolio Expansion - BMY's Growth Portfolio includes drugs such as Opdivo, Orencia, and Yervoy, as the company seeks to expand its pipeline due to the adverse impact of generics on its legacy portfolio [6] - BMY's shares have decreased by 17.8% year-to-date, while the industry has grown by 5.2% [6] Collaboration and New Developments - BMY is collaborating with BioNTech on the development of pumitamig, a bispecific antibody for extensive-stage small cell lung cancer, which has shown a 76.3% confirmed objective response rate in interim data [9][10] - The approval of Cobenfy for schizophrenia broadens BMY's portfolio and validates its acquisition of Karuna Therapeutics, representing a new pharmacological approach to treating schizophrenia [11][12]